Shankar-Hari M, Vale CL, Godolphin PJ, et al. - This prospective meta-analysis of clinical trials demonstrated lower 28-day all-cause mortality in relation to treatment with IL-6 antagonists, vs usual care or placebo, in hospitalized COVID-19 patients.

• Electronic databases were used, and 27 randomized trials with 10,930 patients were analyzed.

• A total of 2,565 patients died by 28 days.

• By 28 days, 1407 of 6449 patients treated with IL-6 antagonists and 1158 of 4481 in the usual care or placebo group had died (summary OR, 0.86).

• IL-6 antagonist with concomitant use of corticosteroids vs without corticosteroids yielded summary odds ratios of 0.78 vs 1.09 for link with 28-day all-cause mortality.